Inmune Bio Inc Stock Price, News & Analysis

INmune Bio, Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Dr. Lowdell, will lead a workshop at the 7th Innate Killer Summit in San Diego from March 30 to April 1, focusing on natural killer (NK) cells in treating solid tumors. The workshop aims to address challenges faced in NK cell therapies. Additionally, INmune will present case studies on INKmune™ showing promising results in three patients, including no side effects and improved disease outcomes. The company continues to advance its clinical trials targeting the innate immune system.

INmune Bio, Inc. (NASDAQ: INMB) recently presented at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's diseases held from March 15-20 in Barcelona, Spain. The company emphasized the growing importance of targeting neuroinflammation in Alzheimer's Disease (AD) treatments, particularly with its Xpro™ therapy. Notable findings include improved synaptic function indicators post-treatment and the use of white matter pathology as a biomarker for predicting AD progression. CEO R.J. Tesi highlighted the significance of these insights in advancing clinical trials and drug development strategies.

INmune Bio (NASDAQ: INMB) presented nine data pieces at the AD/PD^™ 2022 International Conference, held from March 15-20 in Barcelona, focusing on XPro™'s potential in treating Alzheimer’s Disease. This marks the first exposure for many EU and UK clinicians to INmune Bio’s approach targeting neuroinflammation. Key presentations include MRI measures from the Phase 1 trial and insights for Phase 2 trial design. The data emphasizes XPro™’s versatility and novel biomarkers being utilized in clinical strategies.

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company, announced that its CEO, RJ Tesi, MD, will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Dr. Tesi's corporate overview is scheduled for March 16, 2022, at 11:20am ET. Additionally, he will join a fireside chat at the 2022 Maxim Group Virtual Growth Conference on March 30, 2022, at 11:00am ET. INmune Bio is focused on treatments leveraging the immune system to combat diseases like cancer and Alzheimer's. Visit www.inmunebio.com for more information.

INmune Bio, Inc. (NASDAQ: INMB) announced positive results from ongoing clinical trials, including a Phase I trial using INKmuneTM for high-risk myelodysplastic syndrome (MDS) that showed a 60% activation rate of NK cells in a patient after therapy. The company also opened a Phase II trial for treating mild Alzheimer's disease (AD) with XProTM, expecting data in 2023. Financially, INMB reported a net loss of $30.3 million for 2021 but had cash reserves of approximately $74.8 million as of December 31, 2021. Upcoming milestones include expansion of clinical trial sites and additional patient enrollments.

INmune Bio (NASDAQ: INMB) will host a conference call on March 3, 2022, at 4:30 PM ET, to discuss its fourth-quarter results for 2021 and provide a corporate update. The call can be accessed via phone or through a live audio webcast. Participants are encouraged to join several minutes early. A transcript and a replay will be available shortly after the call. INmune Bio is focused on developing therapies that leverage the innate immune system to tackle diseases, with ongoing clinical trials involving products like INB03 and XPro.

INmune Bio, Inc. (NASDAQ: INMB) announced its President and CEO, Raymond J. Tesi, will present at the BIO CEO & Investor Conference in New York City from February 14-17, 2022. The presentation is scheduled for February 15 at 9:15 AM ET. Attendees can schedule virtual one-on-one meetings with the company during the conference. INmune Bio focuses on harnessing the innate immune system to develop treatments for diseases, with ongoing clinical trials for its product platforms, DN-TNF and NK Cell Priming.

INmune Bio (NASDAQ: INMB) has announced a pre-clinical research collaboration with the Chinese University of Hong Kong to evaluate its NK cell priming platform, INKmune™, in treating nasopharyngeal cancer (NPC). This partnership will leverage access to established NPC cancer cell lines. INMB's Chief Executive Officer, RJ Tesi, stated that this collaboration validates INKmune's versatility, targeting a cancer with high mortality rates and limited treatment options. The grant supports pre-clinical work, potentially leading to clinical trials in the UK, Hong Kong, and the US.

INmune Bio, a clinical-stage immunology company (NASDAQ: INMB), announced participation in upcoming investor conferences and a medical meeting. Key events include a panel discussion at LifeSci Advisors' 11th Annual Corporate Access Event on January 6, 2022, and a presentation at H.C. Wainwright Bioconnect Conference on January 10, 2022. Additionally, Professor Mark Lowdell will chair a session at the Allogeneic Cell Therapies Summit Europe on January 19, 2022. The company focuses on developing therapies that utilize the innate immune system to combat diseases such as cancer and Alzheimer’s.